Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept Extension in Pediatric Plaque Psoriasis
NCT00141921Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2005
- Primary completion
- Dec 2011
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 3, open-label, single-arm trial of etanercept in plaque psoriasis, sponsored by Amgen. Primary endpoint: Number of Participants With Adverse Events at 264 weeks. Started Aug 2005; status: completed.
02
Drugs
etanercept
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00141921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141921.